Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Audio By Carbonatix

BOSTON--(BUSINESS WIRE)--Nov 26, 2024--

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 7 th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3 rd at 11:15 am EST.

A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investors & Media section of the company’s website at www.verastem.com. A replay of the webcast will be archived on the website for approximately 90 days following the presentation.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on RAS/MAPK-driven cancers, specifically novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20241126619132/en/

CONTACT: For Investor and Media Inquiries:

Julissa Viana

Vice President, Corporate Communications and Investor Relations

[email protected]

[email protected]

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY

SOURCE: Verastem Oncology

Copyright Business Wire 2024.

PUB: 11/26/2024 07:00 AM/DISC: 11/26/2024 07:00 AM

http://www.businesswire.com/news/home/20241126619132/en